In conclusion, our findings indicate that markers including ESR2, TOMM20, NFE2L2, and CAT not only play a role in mitochondrial oxidative stress but may also influence drug response and cancer recurrence, making them promising biomarkers to predict prognosis in luminal breast cancer. Here, TOMM20 is linked to breast cancer.